Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend

Bulletin Express

08/13

Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.

The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).

The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1146232852"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146232852\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1146232852?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 17:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146232852","market":"us","top_or_hot":-1,"title":"Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.</p>\n<p>The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).</p>\n<p>The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-13 17:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.</p>\n<p>The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).</p>\n<p>The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1146232852","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146232852","pubTimestamp":1786612181,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"广州英诺健制药定于 8 月 25 日召开董事会会议，批准 2026 年上半年业绩并考虑中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.\nThe meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).\nThe announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}